Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3741-3749

  D'Souza, Anita ^a   Dispenzieri, Angela ^c   Wirk, Baldeep ^d   Zhang, Mei Jie ^a   Huang, Jiaxing ^a   Gertz, Morie A ^c   Kyle, Robert A ^x   Kumar, Shaji ^c   Comenzo, Raymond L ^e   Gale, Robert Peter ^g   Lazarus, Hillard M ^h   Savani, Bipin N ⁱ   Cornell, Robert F ^c,i   Weiss, Brendan M ^j   Vogl, Dan T ^j   Freytes, César O ^k   Scott, Emma C ^m   Landau, Heather J ⁿ   Moreb, Jan S ^p   Costa, Luciano J ^r   Ramanathan, Muthalagu ^f   Callander, Natalie S ^b   Kamble, Rammurti T ^l   Olsson, Richard F ^s,t   Ganguly, Siddhartha ^u   Nishihori, Taiga ^q   Kindwall Keller, Tamila L ^v   Wood, William A ^w   Mark, Tomer M ^o   Hari, Parameswaran ^a   more..

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c MAYO CLINIC   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁱ VANDERBILT UNIVERSITY   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k VETERANS AFFAIRS MEDICAL CENTER   (United States)

^l CENTER FOR CELL AND GENE THERAPY   (United States)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o WEILL CORNELL MEDICAL COLLEGE   (United States)

^p UNIVERSITY OF FLORIDA   (United States)

^q H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^r UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^s KAROLINSKA INSTITUTE   (Sweden)

^t UPPSALA UNIVERSITY   (Sweden)

^u UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^v UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^w UNIVERSITY OF NORTH CAROLINA   (United States)

^x NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; MELPHALAN; ALKYLATING AGENT; IMMUNOGLOBULIN LIGHT CHAIN; MYELOABLATIVE AGENT;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOTRANSPLANTATION; CAUSE OF DEATH; CELL TRANSPLANTATION; DISEASE COURSE; FEMALE; HEMATOPOIETIC CELL; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIGHT CHAIN AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NORTH AMERICA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; TREATMENT RESPONSE; YOUNG ADULT; DISEASE FREE SURVIVAL; FACTUAL DATABASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; KAPLAN MEIER METHOD; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS, ALKYLATING; DATABASES, FACTUAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MELPHALAN; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84947461051     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.4015     Document Type: Article

References (30)

1. Skinner M: AL amyloidosis: The last 30 years. Amyloid 7:13-14, 2000
2. Merlini G, Seldin DC, Gertz MA: Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 29:1924-1933, 2011
3. Comenzo RL, Reece D, Palladini G, et al: Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26:2317-2325, 2012
4. Dispenzieri A, Kyle RA, Lacy MQ, et al: Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: A casecontrol study. Blood 103:3960-3963, 2004
5. Skinner M, Sanchorawala V, Seldin DC, et al: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 140:85-93, 2004
6. Mollee PN, Wechalekar AD, Pereira DL, et al: Autologous stem cell transplantation in primary systemic amyloidosis: The impact of selection criteria on outcome. Bone Marrow Transplant 33:271-277, 2004
7. Jaccard A, Moreau P, Leblond V, et al: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083-1093, 2007
8. Mehta J: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 358:91, 2008
9. Dispenzieri A, Gertz MA, Kyle RA, et al: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757, 2004
10. Tsai SB, Seldin DC, Quillen K, et al: High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: Trends in treatment-related mortality over the past 17 years at a single referral center. Blood 120:4445-4446, 2012
11. Gertz MA, Lacy MQ, Dispenzieri A, et al: Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant 48:557-561, 2013
12. Gertz MA, Comenzo R, Falk RH, et al: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79:319-328, 2005
13. Horowitz MM, Przepiorka D, Champlin RE, et al: Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood 79:2771-2774, 1992
14. Cibeira MT, Sanchorawala V, Seldin DC, et al: Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients. Blood 118:4346-4352, 2011
15. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al: Cyclophosphamide-bortezomibdexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 119:4391-4394, 2012
16. Palladini G, Milani P, Foli A, et al: Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: A matched casecontrol study on 174 patients. Leukemia 28:2311-2316, 2014
17. Venner CP, Gillmore JD, Sachchithanantham S, et al: A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia 28:2304-2310, 2014
18. Venner CP, Lane T, Foard D, et al: Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119:4387-4390, 2012
19. Merlini G, Palladini G: Treating advanced cardiac damage in light chain amyloidosis: Still an unmet need. Haematologica 99:1407-1409, 2014
20. Jaccard A, Comenzo RL, Hari P, et al: Efficacy of Bortezomib, Cyclophosphamide and Dexamethasone in treatment of naive patients with high risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica, 99:1479-1485, 2014
21. Pinney JH, Lachmann HJ, Bansi L, et al: Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol 29:674-681, 2011
22. Kumar SK, Gertz MA, Lacy MQ, et al: Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 86:12-18, 2011
23. Dispenzieri A, Gertz MA, Buadi F: What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev 26:137-154, 2012
24. Gertz MA, Lacy MQ, Dispenzieri A, et al: Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 34:1025-1031, 2004
25. Dinner S, Witteles W, Witteles R, et al: The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Br J Haematol 161:367-372, 2013
26. Kourelis TV, Kumar SK, Gertz MA, et al: Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 31:4319-4324, 2013
27. Landau H, Hassoun H, Rosenzweig MA, et al: Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 27:823-828, 2013
28. Palladini G, Dispenzieri A, Gertz MA, et al: New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol 30:4541-4549, 2012
29. Kumar S, Dispenzieri A, Lacy MQ, et al: Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30:989-995, 2012
30. Dispenzieri A, Lacy MQ, Kyle RA, et al: Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19:3350-3356, 2001